Evidence map›Paper›PMID 40217834›Full record

ArticleJournal of clinical medicine2025

Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors.

Sara Elena Campos Ramírez, Alejandro Andrés García, Carmen Blanco Abad, Paula Gomila Pons, Pablo Gómez Mugarza, Sofía Elena Ruffini Egea, Luis Gallart Caballero, Eduardo Polo Marques, Vicente Alonso Orduña

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara Elena Campos RamírezDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.ORCID 0009-0005-5966-6792
Alejandro Andrés GarcíaDepartment of Nuclear Medicine, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain.ORCID 0000-0003-3501-0121
Carmen Blanco AbadDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Paula Gomila PonsDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Pablo Gómez MugarzaDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.ORCID 0009-0006-6856-7013
Sofía Elena Ruffini EgeaDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Luis Gallart CaballeroDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Eduardo Polo MarquesDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Vicente Alonso OrduñaDepartment of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.ORCID 0000-0001-8114-0168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

efficacy of lutetiumlutetium treatmentsafety of lutetiumsurvival analysisunresectable neuroendocrine tumors

Identifiers

PMID40217834
PMCPMC11989597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.